MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/dom.70821

Медицинская библиотека · Diabetes, obesity & metabolism · 2026

Kidney Effects of Finerenone Added to Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease.

Yang Qing, Zhao Lijun, Ma Jing, Ji Shuming, Wang Duolao, Li Jing, Li Sheyu, Liu Fang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Both finerenone and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) improve kidney outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD), but the real-world effectiveness of their combination remains unclear.

METHODS

This retrospective, single-center study recruited people with T2D-CKD receiving finerenone on SGLT-2Is or SGLT-2Is alone in West China Hospital of Sichuan University. Kidney outcomes were compared after 1:4 propensity score matching. The primary outcome was the time from drug initiation to ≥ 30% decline in eGFR. The secondary outcome was the change in chronic eGFR slope.

RESULTS

The matched cohort included 228 SGLT-2Is initiators and 69 finerenone initiators on SGLT-2Is. The baseline mean age was 54.5 years, with eGFR of 68.8 mL/min/1.73 m2 and eGFR slope of -2.1 mL/min/1.73 m2/year. Over a median follow-up of 18.1 months, people receiving finerenone and SGLT-2Is were associated with a reduced risk of ≥ 30% eGFR decline (HR: 0.26; 95% CI: 0.11-0.57) compared to those who received SGLT-2Is only. The between-group difference in post-treatment chronic eGFR slope was -0.74 mL/min/1.73 m2/year (95% CI: -2.95-1.45). However, of those with rapid pre-treatment eGFR decline, the finerenone on SGLT-2Is group experienced significantly greater eGFR decline compared to the SGLT-2Is group (mean difference: -6.28 mL/min/1.73 m2/year; 95% CI: -11.81 to -0.75).

CONCLUSION

Finerenone added to SGLT-2Is was associated with slower eGFR decline in most individuals with T2D-CKD. However, people with rapid pre-treatment eGFR decline may experience accelerated deterioration when finerenone is added. These findings are hypothesis-generating rather than confirmatory, requiring further well-designed and prospective studies for validation.

Для цитирования: Yang Qing, Zhao Lijun, Ma Jing, Ji Shuming, Wang Duolao, Li Jing, Li Sheyu, Liu Fang. Kidney Effects of Finerenone Added to Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease.. Diabetes, obesity & metabolism. 2026. DOI: 10.1111/dom.70821.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.